Preferential Subscription Rights Issue

AI SummaryClose X

Novacyt S.A. is undertaking a rights issue to raise up to €784,736 by offering new shares at €0.40 each, on a 1-for-36 basis, with a subscription period from March 6 to March 17, 2026. The company has secured subscription commitments totaling €605,826, representing over 75% of the planned capital increase, including contributions from Ardenna PTY LTD (€478,526) and members of the Board (€117,300). This capital raise aims to strengthen the company's balance sheet following the acquisition of Southern Cross Diagnostics Pty Ltd. Unaudited financial results for FY 2025 indicate expected revenue of approximately £20.0 million, with a cash position of £19.2 million as of December 31, 2025.

Disclaimer*

UK 100

Latest directors dealings